A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).

Download Full-text

Treatment Decision-Making Among Older Women with Breast Cancer

Journal of Women & Aging ◽

10.1300/j074v18n04_04 ◽

2006 ◽

Vol 18 (4) ◽

pp. 31-47 ◽

Cited By ~ 20

Author(s):

Desirée Ciambrone

Keyword(s):

Breast Cancer ◽

Decision Making ◽

Older Women ◽

Treatment Decision ◽

Treatment Decision Making

Download Full-text

Effect of a Decision Aid on Knowledge and Treatment Decision Making for Breast Cancer Surgery: A Randomized Trial

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70057-5 ◽

2006 ◽

Vol 2006 ◽

pp. 85-86

Author(s):

M. Morrow

Keyword(s):

Breast Cancer ◽

Decision Making ◽

Randomized Trial ◽

Decision Aid ◽

Treatment Decision ◽

Cancer Surgery ◽

Breast Cancer Surgery ◽

Treatment Decision Making

Download Full-text

Factors underlying treatment decision-making for localized prostate cancer in the U.S. and Canada: A scoping review using principal component analysis

Canadian Urological Association Journal ◽

10.5489/cuaj.5538 ◽

2018 ◽

Vol 13 (7) ◽

Cited By ~ 2

Author(s):

Mustafa Andkhoie ◽

Desneige Meyer ◽

Michael Szafron

Keyword(s):

Prostate Cancer ◽

Decision Making ◽

Principal Component Analysis ◽

Scoping Review ◽

Principal Component ◽

Treatment Decision ◽

Localized Prostate Cancer ◽

Key Factors ◽

Treatment Decision Making ◽

Word Cloud

Introduction: The purpose of this research is to gather, collate, and identify key factors commonly studied in localized prostate cancer (LPC) treatment decision-making in Canada and the U.S.Methods: This scoping review uses five databases (Medline, EMBASE, CINAHL, AMED, and PsycInfo) to identify relevant articles using a list of inclusion and exclusion criteria applied by two reviewers. A list of topics describing the themes of the articles was extracted and key factors were identified using principal component analysis (PCA). A word cloud of titles and abstracts of the relevant articles was created to identify complementary results to the PCA.Results: This review identified 77 relevant articles describing 32 topics related to LPC treatment decision-making. The PCA grouped these 32 topics into five key factors commonly studied in LPC treatment decision-making: 1) treatment type; 2) socioeconomic/demographic characteristics; 3) personal reasons for treatment choice; 4) psychology of treatment decision experience; and 5) level of involvement in the decision-making process. The word cloud identified common phrases that were complementary to the factors identified through the PCA.Conclusions: This research identifies several possible factors impacting LPC treatment decision-making. Further research needs to be completed to determine the impact that these factors have in the LPC treatment decision-making experience.

Download Full-text